The study, sponsored by Case Comprehensive Cancer Center, aims to evaluate the efficacy of BIOHM, a novel probiotic, in altering the microbiome profiles of breast cancer patients. Given the increasing interest in the role of the microbiome in cancer treatment and prevention, successful outcomes could position BIOHM as a complementary therapy in breast cancer management. The market for probiotics is growing, with a focus on personalized medicine and microbiome research. If proven effective, this could lead to significant commercial opportunities for BIOHM Health LLC, particularly in oncology. The competitive landscape includes other microbiome-focused therapies, necessitating a robust differentiation strategy. Due diligence should consider regulatory pathways, potential market access challenges, and the need for further studies to establish clinical utility.